U.S. Hereditary Cancer Testing Market (2025 - 2033) Size, Share & Trends Analysis Report By Cancer, By Technology (Cytogenetic, Biochemical, Molecular Testing), By Test Type (Predictive Testing, Diagnostic Testing), By End-use (Hospitals, Clinics), And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Cancer
                        1.2.2. Technology
                        1.2.3. Regional scope
                        1.2.4. Estimates and forecasts timeline.
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Cancer outlook
                        2.2.2. Technology outlook
                        2.2.3. Test Type outlook
                        2.2.4. End Use outlook
                        2.2.5. Regional outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Hereditary Cancer Testing Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook.
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Technological advancements of genetic testing in cancer detection
                            3.2.1.2. Integration with precision medicine
                            3.2.1.3. Growing awareness through public and government initiatives
                            3.2.1.4. Rising prevalence of cancer
                        3.2.2. Market restraint analysis
                            3.2.2.1. High costs and limited insurance coverage
                    3.3. U.S. Hereditary Cancer Testing Market Analysis Tools
                        3.3.1. Industry Analysis – Porter’s
                        3.3.2. PESTEL Analysis
Chapter 4. U.S. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Hereditary Cancer Testing Market: Cancer Movement Analysis
                    4.3. U.S. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2021 to 2033 (USD Million)
                    4.4. U.S. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.5. Lung Cancer
                        4.5.1. Lung Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.6. Breast Cancer
                        4.6.1. Breast Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.7. Colorectal Cancer
                        4.7.1. Colorectal Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.8. Cervical Cancer
                        4.8.1. Cervical Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.9. Ovarian Cancer
                        4.9.1. Ovarian Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.10. Prostate Cancer
                        4.10.1. Prostate Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.11. Stomach/Gastric Cancer
                        4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.12. Melanoma
                        4.12.1. Melanoma Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.13. Sarcoma
                        4.13.1. Sarcoma Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.14. Uterine Cancer
                        4.14.1. Uterine Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.15. Pancreatic Cancer
                        4.15.1. Pancreatic Cancer Market estimates and forecasts 2021 to 2033 (USD Million)
                    4.16. Others
                        4.16.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis
                    5.1. Technology Market Share, 2024 & 2033
                    5.2. Segment Dashboard
                    5.3. U.S. Hereditary Cancer Testing Market by Technology Outlook
                    5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                    5.5. Cytogenetic
                        5.5.1. Cytogenetic Market estimates and forecasts 2021 to 2033 (USD Million)
                    5.6. Biochemical
                        5.6.1. Biochemical Market estimates and forecasts 2021 to 2033 (USD Million)
                    5.7. Molecular Testing
                        5.7.1. Molecular Testing Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Hereditary Cancer Testing Market: Test Type Estimates & Trend Analysis
                    6.1. Test type Market Share, 2024 & 2033
                    6.2. Segment Dashboard
                    6.3. Test type Market by Capacity Outlook
                    6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                    6.5. Predictive Testing
                        6.5.1. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
                    6.6. Diagnostic Testing
                        6.6.1. Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. U.S. Hereditary Cancer Testing Market: End Use Estimates & Trend Analysis
                    7.1. End Use Market Share, 2024 & 2033
                    7.2. Segment Dashboard
                    7.3. End Use Market by End Use Outlook
                    7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                    7.5. Diagnostic Centers
                        7.5.1. Diagnostic Centers Market estimates and forecasts 2021 to 2033 (USD Million)
                    7.6. Hospitals
                        7.6.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
                    7.7. Clinics
                        7.7.1. Clinics Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Recent Developments & Impact Analysis, By Key Market Participants
                    8.2. Company/Competition Categorization
                    8.3. Vendor Landscape
                        8.3.1. List of key distributors and channel partners
                        8.3.2. Key customers
                        8.3.3. Key company market share analysis, 2024
                        8.3.4. Myriad Genetics, Inc.
                            8.3.4.1. Company overview
                            8.3.4.2. Financial performance
                            8.3.4.3. Services benchmarking
                            8.3.4.4. Strategic initiatives
                        8.3.5. Invitae Corporation
                            8.3.5.1. Company overview
                            8.3.5.2. Financial performance
                            8.3.5.3. Services benchmarking
                            8.3.5.4. Strategic initiatives
                        8.3.6. Bio-Rad Laboratories
                            8.3.6.1. Company overview
                            8.3.6.2. Financial performance
                            8.3.6.3. Services benchmarking
                            8.3.6.4. Strategic initiatives
                        8.3.7. CSL Ltd
                            8.3.7.1. Company overview
                            8.3.7.2. Financial performance
                            8.3.7.3. Services benchmarking
                            8.3.7.4. Strategic initiatives
                        8.3.8. Qiagen NV
                            8.3.8.1. Company overview
                            8.3.8.2. Financial performance
                            8.3.8.3. Services benchmarking
                            8.3.8.4. Strategic initiatives
                        8.3.9. Danaher Corporation
                            8.3.9.1. Company overview
                            8.3.9.2. Financial performance
                            8.3.9.3. Services benchmarking
                            8.3.9.4. Strategic initiatives
                        8.3.10. Thermo Fisher Scientific
                            8.3.10.1. Company overview
                            8.3.10.2. Financial performance
                            8.3.10.3. Services benchmarking
                            8.3.10.4. Strategic initiatives
                        8.3.11. Abbott Laboratories
                            8.3.11.1. Company overview
                            8.3.11.2. Financial performance
                            8.3.11.3. Services benchmarking
                            8.3.11.4. Strategic initiatives
                        8.3.12. EUROFINS SCIENTIFIC
                            8.3.12.1. Company overview
                            8.3.12.2. Financial performance
                            8.3.12.3. Services benchmarking
                            8.3.12.4. Strategic initiatives
                        8.3.13. F. HOFFMANN-LA ROCHE LTD
                            8.3.13.1. Company overview
                            8.3.13.2. Financial performance
                            8.3.13.3. Services benchmarking
                            8.3.13.4. Strategic initiatives
                        8.3.14. Illumina, Inc.
                            8.3.14.1. Company overview
                            8.3.14.2. Financial performance
                            8.3.14.3. Services benchmarking
                            8.3.14.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S Hereditary cancer testing market, by cancer, 2021 - 2033 (USD Million)
Table 3 U.S Hereditary cancer testing market, by technology, 2021 - 2033 (USD Million)
Table 4 U.S Hereditary cancer testing market, by test type, 2021 - 2033 (USD Million)
Table 5 U.S Hereditary cancer testing market, by end user, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Hereditary cancer testing market: market outlook
Fig. 14 Hereditary cancer testing competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Hereditary cancer testing market driver impact
Fig. 20 Hereditary cancer testing market restraint impact
Fig. 21 Hereditary cancer testing market strategic initiatives analysis
Fig. 22 Hereditary cancer testing market: Cancer movement analysis
Fig. 23 Hereditary cancer testing market: Cancer outlook and key takeaways
Fig. 24 Hereditary cancer Testing market estimates and forecast, 2021 - 2033
Fig. 25 Hereditary cancer testing Market: Technology movement analysis
Fig. 26 Hereditary cancer testing market: Technology outlook and key takeaways
Fig. 27 Cytogenetic market estimates and forecasts, 2021 - 2033
Fig. 28 Biochemical market estimates and forecasts,2021 - 2033
Fig. 29 Molecular Testing market estimates and forecasts,2021 - 2033
Fig. 30 Hereditary cancer testing Market: Test Type movement analysis
Fig. 31 Hereditary cancer testing Market: Test Type outlook and key takeaways
Fig. 32 Predictive Testing market estimates and forecasts, 2021 - 2033
Fig. 33 Diagnostic Testing market estimates and forecasts, 2021 - 2033
Fig. 34 Hereditary cancer testing Market: End Use movement analysis
Fig. 35 Hereditary cancer testing market: End Use outlook and key takeaways
Fig. 36 Diagnostic Centers market estimates and forecasts, 2021 - 2033
Fig. 37 Hospitals market estimates and forecasts, 2021 - 2033
Fig. 38 Clinics market estimates and forecasts, 2021 - 2033
Fig. 39 Market share of key market players- Hereditary cancer testing market